TICKERNERD
Menu
OCULOCULHealthcare · Biotechnology

OCUL Stock Forecast: Ocular Therapeutix, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$9.99
−1.48% on the day

The 11 Wall Street analysts covering Ocular Therapeutix, Inc. hold a median 12-month price target of $28 — +180.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 35 of 100 as at 18 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$2.2B
Ticker Nerd rank
35 / 100
Median analyst target
$28
Analysts covering
11
Revenue$13.5M+0.1% y/y
Operating income−$82.1M
Net income−$78.8M
Free cash flow−$70.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−4.8%
1M
−9.3%
YTD
−17.7%
1Y
−21.4%
From 52W high
−38.0%
From 52W low
+45.2%
$7
$16
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

OCUL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Ocular Therapeutix, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 18 Sept 2026
35 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
77
Momentum
47
Value
46
Accruals
45
Quality
43
Growth
39
Volatility
36
Size
35
Issuance
24

Revisions (77): Analysts have, on balance, been raising their forecasts.

Issuance (24): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

OCUL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on OCUL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40Oct 25Jan 26Apr 26Jul 26OCULHigh $34Median $28Low $18

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says11 analysts
11 Buy0 Hold0 Sell
Low $18Median $28High $34

The green dot is the last close — the median target sits +180.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
16 Sept 2026Chardan CapitalMaintainsBuy$23
16 Sept 2026HC Wainwright & Co.ReiteratesBuy$25
4 Aug 2026Chardan CapitalMaintainsBuy$23
25 June 2026Chardan CapitalMaintainsBuy$21 → $23
25 June 2026Chardan CapitalMaintainsBuy—
18 June 2026BairdMaintainsOutperform—
18 June 2026BairdMaintainsOutperform$24 → $30
18 June 2026HC Wainwright & Co.ReiteratesBuy$21 → $25
18 June 2026HC Wainwright & Co.ReiteratesBuy—
6 May 2026RBC CapitalReiteratesOutperform—
5 May 2026NeedhamReiteratesBuy—
13 Apr 2026HC Wainwright & Co.ReiteratesBuy—
3 Mar 2026Clear StreetMaintainsBuy—
20 Feb 2026NeedhamMaintainsBuy—
18 Feb 2026Chardan CapitalMaintainsBuy—
9 Dec 2025Chardan CapitalMaintainsBuy—
8 Dec 2025HC Wainwright & Co.MaintainsBuy—
8 Dec 2025NeedhamReiteratesBuy—
25 Nov 2025HC Wainwright & Co.ReiteratesBuy—
5 Nov 2025Chardan CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OCUL appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

OCUL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, Ocular Therapeutix, Inc. returned −21.4% against +16.3% for the S&P 500, dividends included.

OCUL vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120Oct 25Jan 26Apr 26Jul 26OCULS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

OCUL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
0
Fundamentals

Ocular Therapeutix, Inc. (OCUL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−7.0×

Cheaper than 91% of US stocks

Price / sales
42.1×

Cheaper than 6% of US stocks

Price / book
4.2×

Cheaper than 24% of US stocks

EV / EBITDA
−5.4×

Cheaper than 80% of US stocks

Growth & margins
Revenue growth (YoY)
0.1%

Higher than 27% of US stocks

Earnings growth (YoY)
0.1%

Higher than 36% of US stocks

Gross margin
85.1%

Higher than 94% of US stocks

Operating margin
−609.3%

Higher than 7% of US stocks

Net margin
87.3%

Higher than 99% of US stocks

Returns & dividend
Return on equity
−73.0%

Higher than 17% of US stocks

Return on assets
−35.0%

Higher than 12% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Ocular Therapeutix, Inc. (OCUL) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Ocular Therapeutix, Inc. has a market value of $2.2B and an enterprise value of $1.7B.

  • Revenue in the twelve months to 30 June 2026: $52.1M. The latest quarter grew 0.1% year on year.

  • Net income over the same four quarters: −$301.4M, a −579.1% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.42.

  • Free cash flow in the twelve months to 30 June 2026: −$255.1M.

  • Shares outstanding: 219.6M.

  • Trailing P/E: −7.0×; forward P/E: −6.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Ocular Therapeutix, Inc. employs 325 people — $160K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 19 Sept 2026

Data provided by Twelve Data

Peers

OCUL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
OCULOcular Therapeutix, Inc.$2.2B
35
TRVITrevi Therapeutics, Inc.$2.1B
53
SRPTSarepta Therapeutics, Inc.$2.1B
71
URGNUroGen Pharma Ltd.$2.1B
82
PVLAPalvella Therapeutics, Inc.$2.2B
32
NUVBNuvation Bio, Inc.$2.1B
60
GENBGenerate Biomedicines, Inc.$2.2B
1

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Ocular Therapeutix, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest OCUL news & analysis

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 18 Sept 2026neutral

Ocular Therapeutix announced that it granted inducement equity awards to nine newly hired non-executive employees under its 2019 Inducement Stock Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The awards served as an inducement material to each recipient's acceptance of employment.

Why it matters — OCUL watchers may find this relevant as it reflects the company's hiring activity and equity compensation practices, which could be of interest for corporate governance and employee retention considerations.

Ocular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMD

GlobeNewsWire · 15 Sept 2026positive

Ocular Therapeutix announced the successful completion of a Pre-NDA meeting with the U.S. FDA for AXPAXLI (OTX-TKI) in wet AMD. The meeting confirmed the company's plan to submit an NDA based on SOL-1 Week 52 efficacy and safety, interim SOL-R safety, and confirmatory evidence, with submission on track for 4Q 2026 and commercial readiness accelerating ahead of a potential 2027 launch.

Why it matters — This meeting adherence moves AXPAXLI closer to NDA submission and potential approval, and the inclusion of repeat-dosing data supports the company's application for repeat dosing, a key step toward a possible first-in-class TKI for wet AMD.

Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences

GlobeNewsWire · 1 Sept 2026neutral

Ocular Therapeutix announced it will participate in several investor and scientific conferences scheduled for September and October 2026. The company made the announcement in a press release on September 1, 2026.

Why it matters — Conference participation offers OCUL an opportunity to present its work to investors and the scientific community, which watchers may monitor for updates.

Why Is Ocular Therapeutix Stock Gaining Monday?

Benzinga · 17 Aug 2026positive

Ocular Therapeutix stock is trading higher on Monday, reacting to underwhelming data from its rival EyePoint Inc. The rise is attributed to the competitive impact of EyePoint's results on the ophthalmic treatment landscape.

Why it matters — OCUL watchers would care because a rival's weak data could improve Ocular Therapeutix's competitive position in the market.

FAQ

Frequently asked questions about OCUL stock

What is the OCUL stock price forecast for 2026-2027?

The 11 Wall Street analysts covering Ocular Therapeutix, Inc. have a median 12-month price target of $28, with estimates ranging from $18 to $34. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is OCUL stock a buy right now?

Of the 11 analysts covering Ocular Therapeutix, Inc., 11 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Ocular Therapeutix, Inc. 35 out of 100 across roughly 4,600 US stocks as at 18 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank OCUL?

As at 18 Sept 2026, Ocular Therapeutix, Inc. ranks 35 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (77 of 100).

Will OCUL stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +180.3% from the last close, and Ticker Nerd's factor model ranks Ocular Therapeutix, Inc. 35 out of 100 as at 18 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the OCUL stock forecast for 2030?

No analyst covering Ocular Therapeutix, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OCUL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $18 to $34 over the next 12 months.

How has OCUL stock performed over the past year?

Ocular Therapeutix, Inc. returned -21.4% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Ocular Therapeutix, Inc. do?

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing eye treatments for retinal diseases and other conditions of the eye.

What is the latest news on OCUL?

The most recent item we track (GlobeNewsWire, 18 Sept 2026): "Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)". Ocular Therapeutix announced that it granted inducement equity awards to nine newly hired non-executive employees under its 2019 Inducement Stock Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The awards served as an inducement material to each recipient's acceptance of employment.

Company

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing eye treatments for retinal diseases and other conditions of the eye. The company uses its proprietary bioresorbable hydrogel-based formulation technology to create sustained-release therapies designed for ophthalmic use. Its current portfolio includes a marketed product for post-surgical ocular inflammation and pain, along with investigational therapies targeting retinal diseases, glaucoma, ocular hypertension, dry eye disease, and allergic conjunctivitis. Ocular Therapeutix’s products and pipeline are centered on improving drug delivery in ophthalmology, where longer-acting formulations can help address treatment burden and support more consistent therapy administration. Based in Bedford, Massachusetts, the company operates in the specialty biopharmaceutical market with a strong emphasis on ocular care and retinal disease management.

CEO Dr. Pravin U. Dugel M.D. · 325 employees · United States · https://www.ocutx.com